32
Participants
Start Date
December 30, 2023
Primary Completion Date
November 30, 2024
Study Completion Date
January 30, 2026
UB-221
Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution
Lead Sponsor
United BioPharma
INDUSTRY